Skip to main content

Table 1 Summary of donor information

From: ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression

Study Cohorts: Healthy Control ALS P value
Disease progression   Slow Intermediate Rapid  
No. of participants N = 20 N = 15 N = 6 N = 9  
Sex of participants   
 Females 55% (11/20) 33.3% (5/15) 66.7% (4/6) 44.4% (4/9) 0.46c+
 %, (proportion)
 Males 45% (9/20) 66.7% (10/15) 33.3% (2/6) 55.6% (5/9)
 %, (proportion)
Age: Mean (± SD) 65.3 (8.9) 57.2 (10.2) 70.3 (9.7) 66.0 (8.84) 0.40d+
Site of onset     
 Bulbar: %, (proportion)   13.3% (2) 16.7% (1) 22.2% (2) 0.85c−
 Spinal: %, (proportion)   86.7% (13) 83.3% (5) 77.8% (7)
ALSFRS-Ra: mean, ± SD (range)   41.6, ± 3.4 (34–46) 41, ± 2.3 (38–44) 36.8, ± 5.04 (30–46) 0.02d−
ΔFSb: mean, ± SD (range)   0.25, ± 0.1 (0.1–0.45) 0.60, ± 0.1 (0.57–0.67) 1.72, 0.76 (1–3.4) 0.001d−
  1. aALSFRS-R (at diagnosis, when PBMCs were taken; normal score = 48)
  2. bDelta FS ratio (rate of disease progression); (48- ALSFRS-R score at time of diagnosis)/ time onset to diagnosis)
  3. SD Standard deviation
  4. ALSFRS-R Revised Amyotrophic Lateral Sclerosis Functional Rating Scale;
  5. cChi-square test
  6. dANOVA
  7. +p value for comparison between HC and ALS cohort
  8. p value for comparison between ALS subgroups